- •DeepSeek-V4-Flash (53% SHORT) argues that LLY's failure to break higher post-earnings, combined with bearish MACD/RSI signals and low volume at resistance, favors a rejection toward $1167.77 or $1147.73.
Both models highlight a compelling long case supported by a strong Q2 EPS beat, raised full-year guidance, and positive clinical data for retatrutide. They agree that LLY is currently holding a dense support cluster between $1167.77 and $1182.81 (POC/SMA20), with RSI nearing oversold conditions and MACD showing potential for a bullish crossover. This setup suggests a favorable risk-reward swing toward the $1239.83 resistance over a 1-3 week horizon as fundamental momentum reasserts.
All three models flag deteriorating momentum, citing bearish MACD zero-crosses and falling RSI as the stock stalls under $1186.81 resistance. While two models warn of a rejection targeting $1167.77 and $1147.73 due to depressed volume, one model uniquely identifies cross-asset divergence (TLT/XLV weakness) as a catalyst for a deeper pullback toward $1080. The consensus suggests that failure to hold the $1182 shelf will confirm a bearish trend toward the lower value-area edges.
- →Acceptance (4h close) below the 4h support $1167.77 and prior swing structure ~$1155 invalidates the at-support long thesis, signaling a range breakdown rather than a bounce.
Individual Model Analysis
Bull/Bear Competition · case scoresWinner: BULL
Case scores describe the displayed analysis. Average confidence combines this model’s majority runs.
LLY is holding a dense support cluster — 1day support $1182.04, POC $1182.81, and SMA20 — after a strong Q2 beat (+27% EPS surprise), raised FY revenue guidance, and positive retatrutide TRIUMPH data, with 2026 consensus estimates still rising. A calm/bullish regime and a defended high-volume node support a bounce off this level back toward the $1239.83 resistance over the 1-3 week horizon as fundamental momentum reasserts. Entry near support offers favorable geometry with a stop below the 4h $1167.77 support.
LLY has stalled just under 4h resistance ($1186.81) after a bearish MACD zero-cross on both 1day and 4h with falling histograms, and price is pinned on the 1day support/POC shelf ($1182). A break below the 4h support at $1167.77 would open a move toward the lower value-area edge near $1147, as the recent post-earnings drift loses momentum on depressed volume. The short works if sellers reject the resistance retest and force acceptance below the support shelf.
Bull/Bear Competition · case scoresWinner: BEAR
Case scores describe the displayed analysis. Average confidence combines this model’s majority runs.
LLY is pressing against 4h resistance at $1186.81 with deteriorating momentum across both the 4h and 1day timeframes — RSI falling, MACD histogram negative and declining, and a bearish zero-cross on both intervals. The post-earnings range-bound action since the August 4 beat has failed to break higher, and the stock is now retesting resistance from below with depressed volume, setting up a rejection that targets the 4h support at $1167.77 and potentially the value area low near $1147.73 over a 1-3 week swing.
LLY is pulling back to the 4-hour support zone at $1167-$1168, which coincides with the 30-day volume POC at $1182 and the 1-day SMA20, after a strong post-earnings rally that saw the stock beat Q2 estimates by 27% and raise full-year revenue guidance. The calm/bullish macro regime supports mean-reversion buying into value-area support, and the stock's strong fundamental momentum (raised guidance, positive retatrutide data, early access program) provides a catalyst floor. The expected path is a bounce from the POC/support zone toward the 1-day resistance at $1239, with the 52-week high at $1249 as the outer boundary.
Bull/Bear Competition · case scoresWinner: BULL
Case scores describe the displayed analysis. Average confidence combines this model’s majority runs.
LLY presents a compelling long case driven by recent positive clinical results for retatrutide and raised full-year revenue guidance, signaling strong demand for its obesity and diabetes drug portfolio. The stock is currently consolidating near high-volume nodes and key support levels ($1167.77 on the 4h timeframe), with RSI nearing oversold conditions (47.85) and MACD showing signs of a potential bullish crossover, suggesting a favorable risk-reward setup for a swing long.
LLY is extended into a critical resistance zone ( $1186.81 on the 4h interval, $1239.83 on the 1day interval) after a prolonged rally, with technical indicators signaling exhaustion. The stock has failed to sustain momentum above its SMA20 on both intervals, while MACD histogram and RSI are falling, confirming a bearish crossover and loss of upside participation. With no fresh company-specific catalysts and cross-asset divergence (TLT and XLV weakness) , the path of least resistance is a pullback toward the $1080 level, aligning with the low-volume node ( $1112.66) and the next major support zone below the 50-day SMA ( $1170.69) .